Deferiprone
- TRADE NAME: Ferriprox (ApoPharma)
- INDICATIONS: Treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate
- CLASS: Chelator, iron
- HALF-LIFE: 1.9 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Antacids containing iron, aluminum, zinc, Diclofenac, Mineral supplements, Probenecid
PREGNANCY CATEGORY: D
AGRANULOCYTOSIS / NEUTROPENIA
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RENAL.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric